# GALLANT 4 Tesaglitazar vs. Glibenclamide

> **NCT00255541** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 580 (—)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tesaglitazar
- **DRUG:** Glibenclamide

## Key facts

- **NCT ID:** NCT00255541
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 580 (—)
- **Why stopped:** The development program has been terminated
- **Last updated:** 2008-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255541, "GALLANT 4 Tesaglitazar vs. Glibenclamide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00255541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*